Royal College of Surgeons in Ireland
Browse

Valvular heart disease-related mortality between middle- and high-income countries during 2000 to 2019

Download (2.2 MB)
journal contribution
posted on 2025-03-10, 11:07 authored by Makoto Hibino, Hiroki A Ueyama, Michael E Halkos, Kendra J Grubb, Raj Verma, Azeem Majeed, Christoph A Nienaber, Bobby Yanagawa, Deepak L Bhatt, Subodh Verma

Background: Valvular heart disease (VHD) management has evolved rapidly in recent decades, but disparities in health care access persist among countries with varying socioeconomic backgrounds.

Objectives: The purpose of this study was to investigate global mortality trends from VHD and assess the difference between middle- and high-income countries.

Methods: We obtained mortality data from the World Health Organization Mortality Database for VHD and its subgroups (rheumatic valvular disease [RVD], infective endocarditis [IE], aortic stenosis [AS], and mitral regurgitation [MR]) from 2000 to 2019. Age-specific and age-standardized mortality rates per 100,000 persons in middle- and high-income countries were calculated, and trends were analyzed using joinpoint regression.

Results: A total of 93 countries (42 middle-income and 51 high-income) were included in the analysis. Both middle- and high-income countries showed an increasing trend in crude VHD mortality rate. In middle-income countries, the age-standardized VHD-related mortality rate was constant (0.0%/year), with decreasing RVD (-2.7%/year) and increasing IE, AS, and MR (0.8%/year, 2.0%/year, and 2.2%/year, respectively). In high-income countries, the age-standardized VHD-related mortality rate was decreasing (-0.6%/year). However, there was a rapid increase in mortality rate from IE in age ≤39 years after 2009 (7.0%/year). Moreover, there was a decreasing mortality rate from AS after 2015 but an increasing rate from MR after 2013, particularly in age ≥80 years.

Conclusions: Our study identified a rising burden of VHD-related mortality worldwide. The distribution and trends of VHD mortality differed between middle- and high-income countries. Further investigation is needed to understand the underlying etiology of these varying mortality trends in VHD and its subgroups.

Funding

St. Jude Medical, now Abbott

Boston Scientific (Chair, PEITHO trial)

Cleveland Clinic

Contego Medical (Chair, PERFORMANCE 2)

Duke Clinical Research Institute

Mayo Clinic, Mount Sinai School of Medicine

Daiichi Sankyo

Concept Medical

Alleviant Medical Novartis

Population Health Research Institute

Rutgers University

American College of Cardiology

Arnold and Porter

Baim Institute for Clinical Research

Boehringer Ingelheim

CSL Behring

Belvoir Publications

Canadian Medical and Surgical Knowledge Translation Research Group

Cowen and Company

Ferring Pharmaceuticals

Bayer

Abbott

Acesion Pharma

Afimmune

Aker Biomarine

Alnylam

Amarin

Amgen

AstraZeneca

Beren

Boston Scientific

Bristol-Myers Squibb

Cardax

CellProthera

Cereno Scientific

Chiesi

CinCor

Cleerly

Eisai

Ethicon

Faraday Pharmaceuticals

Forest Laboratories

Fractyl

Garmin

HLS Therapeutics

Idorsia

Ironwood

Ischemix

Janssen

Javelin

Lexicon

Lilly

Medtronic

Merck

Moderna

MyoKardia

NirvaMed

Novartis

Novo Nordisk

Otsuka

Owkin

Pfizer

PhaseBio

PLx Pharma

Recardio

Regeneron

Reid Hoffman Foundation

Roche

Sanofi

Stasys

Synaptic

The Medicines Company

Youngene

History

Comments

The original article is available at https://www.sciencedirect.com/

Published Citation

Hibino M, et al. Valvular heart disease-related mortality between middle- and high-income countries during 2000 to 2019. 2024;101133.

Publication Date

28 August 2024

PubMed ID

39817085

Department/Unit

  • Undergraduate Research

Publisher

Elsevier

Version

  • Published Version (Version of Record)